Tokyo, Japan, April 26, 2012 --- "Kirin Kunpeng
(China) Bio-Pharmaceutical Co., Ltd.," a subsidiary of
Kyowa Hakko Kirin Co., Ltd., ("Kyowa Hakko
Kirin") and engaged in developing, manufacturing, and
selling ethical drugs in China, changed its name to
"Kyowa Hakko Kirin China Pharmaceutical Co.,
Ltd.," effective April 23, 2012.
<Reason for the change>
Kyowa Hakko Kirin took full ownership of Kirin Kunpeng
(China) Bio-Pharmaceutical Co., Ltd., as a fully owned
subsidiary in 2010.
Outline of Kyowa Hakko Kirin China Pharmaceutical Co., Ltd.
|
Established
|
June 26, 1997
|
|
Located
|
970 Long Dong Road, Z. J. High-Tech Park, Pudong New
Area, Shanghai, China 201203
|
|
General Manager
|
Toshihiro Onodera
|
|
Capital
|
29.8 million U.S. dollars
|
|
Shareholder
|
Kyowa Hakko Kirin Co., Ltd. (100%)
|
|
Sales
|
230 million CNY (2011)
|
|
Business Areas
|
Development, manufacturing, and sale of ethical drugs
in China
|
|
Main Office
|
Head office, factory: Shanghai
Office: Beijing, Guangzhou, Hangzhou, Chengdu, Hefei
|
Recommend:
